Q-omics provides the consensus-scored DNHD1 profile across patient tissues and cancer cell-line models. DNHD1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DNHD1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, DNHD1 RNA expression shows 20,600 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where DNHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNHD1 survival associations across molecular data types. DNHD1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNHD1 RNA expression–survival associations across cancer types. High DNHD1 expression shows unfavorable associations in KIRC, ACC, COAD and KICH, but favorable associations in HNSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DNHD1 RNA expression.
This table summarizes DNHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DNHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNHD1 shows lower tumor expression in BRCA and THCA and higher tumor expression in KIRC, LIHC, COAD and HNSC. The KIRC box plot shows higher DNHD1 RNA expression in tumor versus normal tissue (log2 FC = +0.299, t-test p < 0.001).
This table shows molecular features associated with DNHD1 in patient tissues and cancer cell lines. In patient samples, DNHD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
